- Home
- PTGX vs XENE Comparison
PTGX vs XENE Comparison
Compare PTGX & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- XENE
- Stock Information
- Founded
- PTGX 2006
- XENE 1996
- Country
- PTGX United States
- XENE Canada
- Employees
- PTGX N/A
- XENE N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- XENE Health Care
- Exchange
- PTGX Nasdaq
- XENE Nasdaq
- Market Cap
- PTGX 2.8B
- XENE 2.5B
- IPO Year
- PTGX 2016
- XENE 2014
- Fundamental
- Price
- PTGX $42.97
- XENE $35.07
- Analyst Decision
- PTGX Strong Buy
- XENE Strong Buy
- Analyst Count
- PTGX 8
- XENE 9
- Target Price
- PTGX $66.50
- XENE $56.22
- AVG Volume (30 Days)
- PTGX 990.2K
- XENE 853.6K
- Earning Date
- PTGX 05-06-2025
- XENE 05-12-2025
- Dividend Yield
- PTGX N/A
- XENE N/A
- EPS Growth
- PTGX N/A
- XENE N/A
- EPS
- PTGX 0.86
- XENE N/A
- Revenue
- PTGX $207,801,000.00
- XENE N/A
- Revenue This Year
- PTGX N/A
- XENE N/A
- Revenue Next Year
- PTGX $7.13
- XENE $1,553.36
- P/E Ratio
- PTGX $50.68
- XENE N/A
- Revenue Growth
- PTGX N/A
- XENE N/A
- 52 Week Low
- PTGX $24.22
- XENE $26.74
- 52 Week High
- PTGX $60.60
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- PTGX 43.08
- XENE 50.20
- Support Level
- PTGX $41.29
- XENE $34.47
- Resistance Level
- PTGX $46.12
- XENE $36.44
- Average True Range (ATR)
- PTGX 1.83
- XENE 1.44
- MACD
- PTGX -0.19
- XENE -0.19
- Stochastic Oscillator
- PTGX 27.81
- XENE 28.63
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.